AstraZeneca and Daiichi Sankyo's Lung Cancer Drug Shows Promise, Shares Fall
Results from AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan clinical trials were released this week. The antibody drug, also known as Dato-DXd, was developed in partnership between the two companies and aims to help patients with the most common lung cancer live longer without worsening their condition when compared to standard treatments. However, the announcement fell short of expectations, leading to a decline in AstraZeneca's shares.
The late-stage phase III trial displayed an improvement in progression-free survival when assessed against standard chemotherapy for patients with non-small cell lung cancer who had prior treatments. Despite this, investors expressed concerns with the effectiveness of the drug, as "clinically meaningful" results were absent from the report. This led to a drop of 8% in AstraZeneca's shares Jul. 3, the lowest they've seen since March and a drop of 4% in Daiichi Sankyo's shares.
Susan Galbraith, executive vice president, oncology R&D at AstraZeneca, said: “These first Phase III trial results from the datopotamab deruxtecan clinical program provide compelling evidence for the potential role this (antibody) can play in treating patients with lung cancer.” And Ken Taeshita, global head of oncology R&D at Daiichi Sankyo said that he "look(s) forward to the final overall survival analysis."
Dato-DXd plays a crucial role in both companies' pipelines, and while the results show promise, they don't quite hit the mark when it comes to investor expectations.
most read
Dow to Shut Down Three Upstream European Assets
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
Oxea Returns to its Roots
Oxea is returning to its old name and its roots.
Supply Chain and Logistics Trends in the Chemical Industry
This interview covers key results of the study ‘Success Factor Supply Chain Management and Logistics in the Chemical Industry 2024’ by Solventure, Aimms and Miebach.
Valerie Diele-Braun Leaves IMCD
Valerie Diele-Braun resigned from her position as CEO and member of the Executive Board of IMCD at the end of April for personal reasons.
Orion Announced Plans to Shut Down Carbon Black Plants
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.